Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal High-Risk or Very High-Risk Patients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

NCT05998122 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT05998122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05998122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal High-Risk or Very High-Risk Patients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2023
Completion date
December 31, 2028
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-pd-1, locally advanced rectal cancer, total neoadjuvant treatment